Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Sir Andrew Pollard will discuss epidemiology of typhoid and the development of vaccines to control enteric fever using a ground-breaking controlled human infection model in Oxford and large-scale evaluation in the two low income countries. Current understanding of immunological correlates of protection will be outlined and an update on deployment of vaccines to protect the most vulnerable populations presented. There remain a number of challenges ahead but millions of children are now being protected by the roll out of the typhoid vaccine.

Sir Andrew is Director of the Oxford Vaccine Group at the University of Oxford and an honorary consultant paediatrician (infectious disease and immunology) at Oxford Children’s Hospital. He received a knighthood in the Queen’s Birthday Honours in 2021 for services to Public Health and the Order of Medical Merit from the Federal Republic of Brazil in 2022. 

His research includes the design, development and clinical evaluation of vaccines including those for typhoid, meningococcus, Haemophilus influenzae type b, pneumococcus, plague, pertussis, influenza, rabies, coronavirus and Ebola. His work on pneumococcal and meningococcal vaccines has been used in global public health policy. His studies on typhoid both using the human challenge model and in field sites supported the WHO prequalification of a new typhoid conjugate vaccine and WHO recommendations for its use in countries with a high burden of disease with more than 50 million vaccinated since 2021. He was the chief investigator for the clinical trials of the Oxford-AstraZeneca vaccine in 2020 in 24,000 participants in UK, South Africa and Brazil, which led to authorisation of the vaccine for use in more than 180 countries with over 3 billion doses distributed and award of the Copley Medal by the Royal Society in 2022. He has supervised 50 PhD students and his publications includes over 700 manuscripts. He chairs the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation, and was a member of WHO’s Strategic Advisory Group of Experts (2016-2022). He chaired the European Medicines Agency scientific advisory group on vaccines (2012–2020). He received the Bill Marshall Award of the European Society for Paediatric Infectious Disease (ESPID) in 2013, the ESPID Distinguished Award for Education and Communication in 2015 and the Rosén von Rosenstein medal in 2019 from the Swedish Society of Medicine, the James Spence Medal from the Royal College of Paediatrics and Child Health in 2022. He is chair of the Knoop Charitable Trust and is a trustee of the Jenner Vaccine Foundation, the Academy of Medical Sciences and the Oxford Philharmonic Orchestra. 

Forthcoming events

Richard Doll Seminar - Adventures in Digital Health Research: Alcohol, Coffee, and Arrhythmias

Tuesday, 03 September 2024, 1pm to 2pm @ Richard Doll Lecture Theatre, Richard Doll Building, OldRoad Campus, University of Oxford, OX3 7LF